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Abstract
Purpose: We sought to identify genes of clinical significance to predict survival and the risk for colorectal liver metastasis
(CLM), the most common site of metastasis from colorectal cancer (CRC).
Patients and Methods: We profiled gene expression in 31 specimens from primary CRC and 32 unmatched specimens of
CLM, and performed Significance Analysis of Microarrays (SAM) to identify genes differentially expressed between these two
groups. To characterize the clinical relevance of two highly-ranked differentially-expressed genes, we analyzed the
expression of secreted phosphoprotein 1 (SPP1 or osteopontin) and lymphoid enhancer factor-1 (LEF1) by
immunohistochemistry using a tissue microarray (TMA) representing an independent set of 154 patients with primary CRC.
Results: Supervised analysis using SAM identified 963 genes with significantly higher expression in CLM compared to
primary CRC, with a false discovery rate of ,0.5%. TMA analysis showed SPP1 and LEF1 protein overexpression in 60% and
44% of CRC cases, respectively. Subsequent occurrence of CLM was significantly correlated with the overexpression of LEF1
(chi-square p=0.042), but not SPP1 (p=0.14). Kaplan Meier analysis revealed significantly worse survival in patients with
overexpression of LEF1 (p,0.01), but not SPP1 (p=0.11). Both univariate and multivariate analyses identified stage
(p,0.0001) and LEF1 overexpression (p,0.05) as important prognostic markers, but not tumor grade or SPP1.
Conclusion: Among genes differentially expressed between CLM and primary CRC, we demonstrate overexpression of LEF1
in primary CRC to be a prognostic factor for poor survival and increased risk for liver metastasis.
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Introduction
Despite considerable progress in the diagnosis and treatment of
colorectal cancer (CRC) over the last few decades leading to a
significant decline in cancer-related mortality,[1,2] CRC remains
a major public health problem throughout the world. In the
United States, CRC is the third most common cancer and is also
the third leading cause of cancer death in men and women
combined.[3]
Worldwide it represents the third most common cancer and
second most common cause of cancer-related death.[4] Once
metastasis has occurred in CRC, a complete cure of the disease is
unlikely. Therefore, there is a need for better understanding of the
molecular mechanisms underlying the metastatic phenotype that
may provide information leading to the development of drugs to
control or prevent metastatic disease.[1]
Colorectal liver metastasis (CLM), occurring in about 60% of
CRC patients during the course of their treatment, is the most
common distant metastasis from CRC. Several clinical prognostic
factors, such as lymph node status and size of the primary tumor,
have been identified for CLM.[5,6] However, little is known about
the prognostic significance of molecular markers for CLM.
Recent development and application of human genome and
high-throughput technologies, such as DNA microarrays, allows
us to simultaneously examine thousands of genes, leading to a
much better understanding of carcinogenesis - a great step toward
individualized personal medicine.[7] Published studies on CRC
gene expression profiling have mainly examined normal vs.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16636tumor tissues or different stages of CRC,[8,9] or treatment
outcomes by the differences in gene expression profiling.[10,11]
To identify molecular markers of clinical significance, we used
DNA microarrays to compare the gene-expression profiles of
specimens from primary CRC and specimens from CLM. We
reasoned that genes upregulated in metastasis might also be
relatively overexpressed in a subset of clinically-aggressive
primary CRC. After identifying upregulated CLM-signature
genes, we used tissue microarrays (TMAs) to study the protein
expression of selected signature genes in an independent cohort of
primary CRC, to correlate their expression with clinical
significance and outcome.
Results
Identification of gene signatures distinguishing CLM
from primary CRC by expression profiling
To survey the differentially expressed genes between CLM and
primary CRC (also compared to normal liver, a potential tissue
contaminant of CLM), we used cDNA microarrays containing
,19,500 unique genes to profile the gene expression in 31
primary CRC specimens from 30 patients, and 32 unmatched
CLM specimens from 31 patients who underwent liver resection.
We then performed supervised analysis using SAM (with a
Student’s
t-test metric) and identified 1,186 discriminatory cDNAs
(corresponding to 963 unique genes) with significantly higher
expression in CLM when compared to primary CRC, and to
normal liver (previously profiled,[12]), with a false discovery rate
(FDR) of ,0.005% (Table S2). The top 35 differentially
expressed genes are shown in Fig. 1. The 20 highest-ranking
genes were SPP1, CXCR4, GPNMB, LOX, CD53, AIF1, ARHGDIB,
SLC12A2, PRG1, SPARC, CD3D, DZIP1, PEG3, FYB, ITM2A,
SLA, IGLC2, MGP, LEF1, and MAF. Similar results were obtained
using SAM with a non-parametric, Wilcoxin rank-based analysis
(Table S3).
LEF1 protein overexpression in CRC correlates with CLM
and overall survival
Primary CRC specimens with relative increased expression of
CLM signature genes might exhibit increased metastatic
potential. To further study the significance of such potential
biomarkers identified via SAM analysis, we examined the protein
expression of two highly ranked and biologically plausible
signature genes (for which IHC-validated antibodies were also
available), SPP1 (linked to metastasis[13]) and LEF1 (lymphoid
enhancer factor-1; involved in WNT signaling[14]), in an
independent TMA cohort of CRC specimens. Examples of
antibody staining by intensity are shown in Fig. 2. Correlation of
SPP1 or LEF1 overexpression (IHC scored +2o r+3) with
subsequently occurring CLM is shown in Table 1. LEF1
overexpression was significantly correlated with CLM (Fisher’s
exact test, p=0.042). No significant correlation was observed
between SPP1 overexpression and subsequent CLM.
We used Kaplan-Meier analyses to investigate the impact of
SPP1 or LEF1 overexpression on overall survival. LEF1
overexpression was significantly associated with worse survival
(log-rank p,0.01; Fig. 3B). In contrast, SPP1 overexpression was
not significantly correlated with a worse outcome, though there
was a trend toward poor survival (log-rank p=0.11; Fig. 3A)
LEF1 is a significant prognostic factor in multivariate
analysis
As expected, higher stage was found to be significantly
associated with worse overall survival. In the univariate model,
the hazard ratios (HRs) for stage 2, 3, and 4 vs. 1 was 1.63, 3.47
Figure 1. Heatmap showing the top 35 ranking genes, based on SAM analysis, with greatest increased expression in CRC with CLM
compared to primary CRC or normal liver. Rows represent individual genes and columns represent individual tissue samples. In each tissue
sample, the log2 ratio of abundance of transcripts of each gene relative to its mean abundance across all tissue samples is depicted according to the
color score shown at the bottom. Grey indicates missing or excluded data.
doi:10.1371/journal.pone.0016636.g001
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model, the HRs are 1.74, 3.74 (p=0.01), and 13.74 (p,0.001),
respectively. The HRs were also statistically significant for LEF1
overexpression in both the univariate and multivariate models -
1.78 (p,0.05) and 1.66 (p,0.05), respectively. Neither SPP1
overexpression nor tumor grade was significantly associated with
survival in either analysis. Table 2 summarizes the HRs and 95%
confidence intervals for the variables in both models.
Discussion
In our study, we sought to identify signatures of metastasis
embedded in a subset of primary tumors, which might predict
clinically-aggressive behavior [15]. Using supervised SAM analy-
sis, we identified 963 unique genes that are significantly
overexpressed in CLM vs. primary CRC (and potentially
contaminating normal liver tissue). In an independent set of tissue
microarrays, we examined two highly-ranked genes (LEF1 and
SPP1) as surrogate biomarkers for the CLM signature, and
demonstrated that overexpression of LEF1, but not SPP1, in the
primary CRC tissues correlates with a statistically significant
increased risk of CLM, albeit its sensitivity and specificity in
predicting liver metastasis were modest. In addition, independent
of tumor stage, overexpression of LEF1, not SPP1, denotes a poor
prognosis for survival.
LEF1 was initially identified as a pre-B and T-lymphoid-specific
gene encoding a DNA-binding protein of high mobility group
(HMG) proteins.[16,17] It is a member of the T-cell factor/
lymphoid-enhancing factor (TCF/LEF) family of transcription
factors, which acts through the Wnt signaling pathway[18,19,20] to
regulate gene expression and coordinate many cellular processes in
normal development and tissue homeostasis, and, when deregulat-
ed, in colonic tumorogenesis and metastasis. Upon Wnt stimulation,
LEF1 or other TCF/LEF-family transcription factors associate with
b-catenin, a key cytoplasmic/nuclear mediator of Wnt pathway,
and activate Wnt-responsive target genes. In contrast, without Wnt
stimulation, glycogen synthase kinase (GSK)-3 (in a complex with
APC) constitutively phosphorylates b-catenin, resulting in its
proteasome-dependent degradation.[21] Although genetic and
epigenetic changes have been documented in several targets
throughout the pathway, mutation in either APC or b-catenin
appears to be a crucial element in CRC carcinogenesis.[22] The
LEF1 gene itself is not normally expressed in the adult intestinal
epithelium, but only observed in the embryos while development is
in progress. However, its overexpression has been well documented
in CRC tumorigenesis[23], and denotes aberrant activation of the
Figure 2. Immunohistochemical staining and assessment of SPP1 or LEF1 in representative core sections from the CRC tissue
microarray. Staining of SPP1 and LEF1 were respectively visualized in the cytoplasm and nuclei of cancer cells (X 400 magnification).
doi:10.1371/journal.pone.0016636.g002
Table 1. Correlation between liver metastasis and SPP1 or LEF1 overexpression
a.
SPP1 Overexpression (No. of patients) LEF1 Overexpression (No. of patients)
Liver metastasis Yes No p Yes No p
Yes 24 10 16 10
No 66 51 41 63
0.14 0.042
aAs a predictor for liver metastasis, the sensitivity, specificity, positive predictive value, and negative predictive value for overexpression of SPP1 in the primary colon
cancer tissue were 26.7%, 83.6%, 70.6%, and 70.6%, respectively. In contrast, the sensitivity, specificity, positive predictive value, and negative predictive value for
overexpression of LEF1 are 28.1%, 86.3%, 61.5%, and 60.6%, respectively. Despite that the sensitivity and specificity were higher in LEF1, both showed modest
performance.
doi:10.1371/journal.pone.0016636.t001
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complex. Indeed, LEF1 is a direct transcriptional target of the
LEF1/b-catenin complex[23], indicating a positive feedback loop
for Wnt signaling, and suggesting LEF1 might be useful as a
prognostic biomarker of Wnt pathway activation. Our findings are
consistent with a prior study showing nuclear (active) b-catenin
staining to be prognostic in colon cancer,[24] and highlight a role of
Wnt signaling in colon cancer progression and liver metastasis.
As the prefix "osteo" suggests, osteopontin (or OPN, also known
as secreted phosphoprotein 1 [SPP1], bone sialoprotein I, early T-
lymphocyte activation 1) was initially recognized as an important
glycosylated, adhesive phosphoprotein in bone.[25] Since then,
several lines of evidence have shown its role in controlling
tumorigenicity, progression and metastasis via its diverse ability as
a cell-matrix mediator to interact with a variety of factors such as
cell surface receptors (integrins and CD44), secreted proteases
(matrix metalloproteinases and urokinase plasminogen activator),
and growth factor/receptor pathways (TGF/EGFR and HGF/
Met).[26] Overexpression of SPP1 has been reported in several
human cancers, including lung, breast and colon cancers. In a
gene-expression profiling study, Agrawal et al identified SPP1 as a
lead marker correlating with CRC progression, and strongly
expressed in CLM.[27,28,29] Most recently, Rohde et al observed
that overexpression of SPP1 is indicative of poor survival in CRC
and is significantly correlated with CLM.[30] In addition,
overexpression of SPP1 correlates with increased immunohisto-
chemical staining of b-catenin and, in an in vivo model, with Wnt
activating mutations. These data suggest a crucial role of SPP1 in
CRC progression and metastasis likely via molecular cross-talk
with the Wnt pathway. Our results partially corroborate with
published data in that we observe a trend towards poorer survival
and CLM with SPP1 overexpression, though it is not statistically
significant. This difference may be due to a smaller sample size
and/or shorter follow-up time. Nonetheless, our data suggest that
the overexpression of LEF1 is a stronger prognostic factor than
SPP1 in correlating overall survival and CLM.
Though our analysis focused primarily on LEF1 and SPP1, other
highly-ranked signature genes with increased expression in CLM
compared to primary CRC also have biological functions consistent
with roles in tumor progression, and might have prognostic utility.
For example, CXCR4 (Chemokine (C-X-C motif) receptor 4) has
been implicated in breast [31] and colon cancer metastasis.[32]
LOX (lysyl oxidase) was shown to be associated with hypoxia where
it functions in metastasis and predicts poor outcome in breast
Figure 3. Kaplan-Meier overall survival curves based on (A) SPP1 overexpression (log rank p=0.11) or (B) LEF1 overexpression (log
rank p,0.01).
doi:10.1371/journal.pone.0016636.g003
Table 2. Univariate and Multivariate Hazard Ratios From Cox
Proportional Hazards Regression Models.
Variable P Hazard Ratio 95% Confidence interval
Univariate analysis
LEF1 0.03 1.66 1.04–2.63
SPP1 0.37 1.25 0.77–2.02
Stage
1*
2 0.36 1.63 0.57–4.63
3 0.02 3.47 1.27–9.50
4 ,.0001 12.63 4.86–32.84
Tumor grade
1*
2 0.60 0.69 0.17–2.83
3 0.96 1.04 0.24–4.52
Multivariate analysis
LEF1 0.02 1.78 1.09–2.89
SPP1 0.54 0.85 0.51–1.43
Stage
1*
2 0.31 1.74 0.60–5.02
3 0.01 3.74 1.35–10.39
4 ,.0001 13.74 5.19–36.36
Tumor grade
1*
2 0.48 0.59 0.14–2.54
3 0.82 0.84 0.19–3.76
*Reference category.
doi:10.1371/journal.pone.0016636.t002
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nectin) was identified among genes that mark and mediate breast
cancer metastasis.[34] Further studies are needed to characterize
these and other signature genes in CRC progression.
Much of the published data comparing gene expression profiles
from primary CRC vs. CLM have reported the differences in up-
or down-regulated genes.[35,36,37,38,39,40,41,42,43,44] To the
best of our knowledge, our data are the first to identify the
expression of LEF1 as a predictor of overall survival, and an
indicator of CLM. Comparisons of primary CRC vs. CLM, or of
primary CRC associated with or without CLM, have identified
gene signatures with relevance to colorectal cancer progres-
sion.[27,30,35,36,37,38,39,40,41,43] However, there are minimal
overlaps between our CLM signature genes and the top-ranking
CLM/progression-associated genes reported in these studies
(Table 3). Several issues may explain the discordance among
studies, such as: variability in patient cohorts, technical differences
(the composition of the microarrays used, study design, statistical
methodologies), and variability in the use of independent cohorts
of patients to validate candidate prognostic genes.[45]
In conclusion, our study shows that overexpression of LEF1 in
primary CRC correlates with a higher risk of CLM and denotes
poor overall survival. It is a stronger predictor than SPP1, a
marker reported in previous transcriptome studies. High-through-
put gene expression profiling technology has revealed new insights
into the molecular heterogeneity of CRC and identified new and
better molecular markers for risk stratification. This holds promise
for personalized medicine and improved targeted therapy. To
achieve these goals, further studies are needed to understand the
functional roles and clinical implications of LEF1, SPP1 and other
signature genes for CLM.
Materials and Methods
Patients and Tumor Specimens
Freshly frozenCRCspecimens(fromSanta ClaraValleyMedical
Center) and CLM specimens (from Stanford University Medical
Center)wereused for gene expression profiling analysis.Weused 31
primaryCRCspecimens from 30 patients (14males and 16 females;
age range: 36 to 80; stage I/II/III/IV=1/10/11/8, diagnosed
between 2000 and 2004), and 32 CLM specimens from 31 patients
(16 males and 15 females; age range: 40 to 82). Tissue microarrays
were constructed with paraffin blocks from 154 CRC cases (84
males and 70 females; age range: 27 to 92; stage I/II/III/IV=26/
46/38/44) with median follow-up of 3.0 years (range: 0.6–15.3
years). Study protocols were approved by Institutional Review
Board (IRB) both at Stanford University Medical Center (IRB #
12473) and Santa Clara Valley Medical Center, a Stanford-
affiliated teaching hospital, (IRB #07/28/00-03 and #2/22/2002-
04). Individual informed consent was obtained from all participants
involved in the gene expression profiling protocols and was waived
in the TMA study by IRB due to the use of coded data and
retrospective nature of the study. Clinical characteristics of the
patient cohorts are summarized in Table S1.
Gene expression profiling
To confirm that the sample was representative of the case, a
frozen section from each specimen was first prepared and
examined. Tissue was then homogenized in Trizol reagent
(Invitrogen, Carlsbad, CA), and total RNA isolated per the
manufacturer’s protocol. RNA quality was assessed by gel
electrophoresis. Gene expression profiling was performed as
described previously.[46] Briefly, using microarrays of comple-
Table 3. Overlap of CLM genes with top-ranking CLM/progression genes from other published studies.
Gene Symbol Overlapping with Other Studies Gene Name
AGR2 Ki et al.[35], Tackels-Horne et a.[40] ANTERIOR GRADIENT 2 HOMOLOG (XENOPUS LAEVIS)
CD44* Ki et al.[35], Lin et al. [38]; Takayama et al.[47], CD44 ANTIGEN (INDIAN BLOOD GROUP)
CDC2 Ki et al.[35], Takahashi et al.[45] CELL DIVISION CYCLE 2, G1 TO S AND G2 TO M
CDH17 Ki et al.[35], Tackels-Horne et a.[40] CADHERIN 17, LI CADHERIN (LIVER-INTESTINE)
CEACAM5 Ki et al.[35], Tackels-Horne et a.[40] CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE 5
CEACAM6 Ki et al.[35], Tackels-Horne et a.[40] CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE
6 (NON-SPECIFIC CROSS REACTING ANTIGEN)
CKS2 Li et al.[37], Lin et al. [38] CDC28 PROTEIN KINASE REGULATORY SUBUNIT 2
EFEMP1 Ki et al.[35] EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 1
HNRPA1 Ki et al.[35], Li et al.[37] HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1
MAD2L1 Ki et al.[35], Li et al.[37] MAD2 MITOTIC ARREST DEFICIENT-LIKE 1 (YEAST)
MMP2 Ki et al.[35], Takayama et al.[43]; MATRIX METALLOPEPTIDASE 2 (GELATINASE A, 72KDA GELATINASE,
72KDA TYPE IV COLLAGENASE)
S100P Ki et al.[35], Li et al.[37] S100 CALCIUM BINDING PROTEIN P
SPP1 Agrawal et al.[27], Rohde et al.[30 87] SECRETED PHOSPHOPROTEIN 1 (OSTEOPONTIN, BONE SIALOPROTEIN I,
EARLY T-LYMPHOCYTE ACTIVATION 1)
TIMP1* Ki et al.[35], Takayama et al.[43];
Takahashi et al.[41]
TIMP METALLOPEPTIDASE INHIBITOR 1
TOP2A Ki et al.[35], Takahashi et al.[41] TOPOISOMERASE (DNA) II ALPHA 170KDA
VAV3 Ki et al.[35], Kleivi et al.[36] VAV 3 ONCOGENE
Gene names are according to the DAVID Bioinformatics Database.
http://david.abcc.ncifcrf.gov/tools.jsp.
*indicates genes present in three studies.
doi:10.1371/journal.pone.0016636.t003
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Genomics Facility) containing ,40,000 nonredundant cDNA
clones, representing ,19,500 unique UniGene clusters (i.e.,
genes), we hybridized Cy5-labeled total RNA from the tumor
specimens, along with Cy3-labeled universal reference mRNA
(pooled from 11 different cancer cell lines). We imaged arrays
using an Axon GenePix 4000B scanner (Molecular Devices,
Sunnyvale, CA), extracted fluorescence ratios (ratio of the
specimen value to the reference value) using the GenePix software,
and entered the data into the Stanford Microarray Database[47]
for subsequent analysis. The microarray data are accessible from
the Gene Expression Omnibus (Accession GSE22834). cDNA
microarray expression data from normal liver specimens were
previously published.[12]
TMA construction and immunohistochemistry
A tissue arrayer (Beecher Instruments, Sun Prarie, WI) was used
to construct a primary CRC tissue microarray as described,[48]
comprising of 154 primary colorectal tumors each represented by
two 6-mm cores. A 4-mm section was cut from the tissue
microarray block, deparaffinized in Citrisolv (Fisher Scientific,
Hampton, NH) and hydrated in a graded series of alcohol
solutions.
For immunohistochemical staining (IHC), anti-osteopontin
(SSP1) mouse monoclonal antibody (Novocatra, Newcastle, UK)
and anti-LEF1 (lymphoid enhancer factor-1) rabbit polyclonal
antibody (Abcam, Cambridge, MA) were used at 1:100 and 1:500
dilutions respectively, and incubated overnight at 4uC. Chromo-
genic detection was then done using a peroxidase-conjugated
secondary antibody and DAB reagents provided with the Envision
detection kit (DAKO, Carpinteria, CA). SPP1 expression was
scored as positive if distinct cytoplasmic staining was present in
more than 10% of tumor cells. LEF1 expression was scored as
positive when distinct nuclear staining was present in more than
10% of tumor cells. Weak cytoplasmic staining of LEF1 was not
counted. The staining intensity was graded on a semiquantitative
score (0, negative; 1+, weak; 2+, moderate; and 3+, strong).
Survival analysis was performed in two groups depending on the
score: overexpression (2+ and 3+) vs. the remainder (0 or 1+).
Immunostains were scored by two pathologists (M.vdR. and YLC)
blinded to the clinical data.
Statistical Analysis
For cDNA microarray data, ratios were globally normalized by
array and median-centered by gene. We included for analysis the
4,824 cDNAs (corresponding to 3,413 unique genes) that were
well-measured (intensity/background .2 in either the test or
reference channel) in at least 50% of samples, and variably
expressed (.4-fold change from the median) in at least 3 samples.
Two-class Significance Analysis of Microarrays (SAM) [49] was
used to identify genes that were differentially expressed in CLM
compared to primary CRC and normal liver (a potential
contaminant of CLM), with statistical significance assessed by a
false discovery rate (FDR).
For clinicopathological data, a chi-square test or Fisher’s exact
test (two-tailed) was used to compare differences in categorical
variables across patient groups. Kaplan-Meier methods were used
to estimate overall survival. We used both univariate and
multivariate Cox proportional hazard regression model to assess
the prognostic independence of variables (LEF1, SPP1, stage and
tumor grade) for survival. Statistical analyses were performed with
the SAS System software, release 9.1.3 (SAS Institute Inc., Cary,
NC).
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